Hostname: page-component-54dcc4c588-54gsr Total loading time: 0 Render date: 2025-10-13T13:44:34.273Z Has data issue: false hasContentIssue false

Long-Acting Injectable Antipsychotics: Are They the Missing Link in Early Psychosis Treatment?

Published online by Cambridge University Press:  26 August 2025

I. M. Lopes*
Affiliation:
Psychiatry, ULS Arco Ribeirinho
D. Seabra
Affiliation:
Psychiatry, USL Arco Ribeirinho
G. Santos
Affiliation:
Psychiatry, ULS Arco Ribeirinho
N. Ramalho
Affiliation:
Psychiatry, ULS Arco Ribeirinho
T. Coelho Rocha
Affiliation:
Psychiatry, ULS Arco Ribeirinho
J. Alves Leal
Affiliation:
Psychiatry, ULS Arco Ribeirinho
J. F. Cunha
Affiliation:
Psychiatry, ULS Barreiro, Barreiro
J. Moura
Affiliation:
Psychiatry, ULS Arco Ribeirinho
D. Santos
Affiliation:
Psychiatry, ULS Arco Ribeirinho
A. Garcia
Affiliation:
Psychiatry, ULS Arco Ribeirinho
M. Rosa
Affiliation:
Psychiatry, ULS Arco Ribeirinho
C. Pires
Affiliation:
Psychiatry, ULS Arco Ribeirinho
L. Lopes
Affiliation:
Psychiatry, ULS Alto Minho, Viana do Castelo
M. Cameira
Affiliation:
Psychiatry, ULS São José, Lisboa, Portugal
*
*Corresponding author.

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Introduction

Research into early interventions following a first episode of psychosis (FEP) has enabled a focused approach on prognostic-modifying factors. Among these, poor medication adherence contributes to relapse, as well as cognitive and functional deterioration. Several studies report discontinuation rates of oral antipsychotics (OAPs) after FEP at 70%, regardless of the prescribed OAP. The early introduction of long-acting injectable antipsychotics (LAIAs) could present an alternative.

Objectives

This study aims to review the efficacy of LAIAs in the early stages of psychosis and compare the most relevant international guidelines on this topic.

Methods

Methodology: A non-systematic literature review using the keywords “long-acting injectable” and “first episode psychosis,” limited to articles published in English and Portuguese in the last 10 years from the PubMed®/MEDLINE® database, and clinical practice guidelines on psychosis, schizophrenia, and FEP from NICE, APA, and RANZCP.

Results

Despite frequent selection biases (such as reserving LAIAs for patients with worse prognostic factors), significant benefits of LAIAs over OAPs in preventing hospitalization and relapse during the early phases of psychosis are consistently reported. LAIAs reduce non-adherence due to forgetfulness or reduced insight, while their different pharmacokinetics minimize withdrawal symptoms, drug interactions, and fluctuations in plasma concentration, enhancing tolerability. No second-generation LAIA was found to be clearly superior in terms of efficacy. Various guidelines recommend offering this treatment option early, favoring an informed and collaborative decision-making process. However, despite documented benefits in robust studies, they do not consider LAIAs as a first-line treatment.

Conclusions

Discussion/Conclusions: Significant variations in the proportion of patients on LAIAs across countries suggest that factors other than efficacy may influence its use. Greater understanding of these factors could help identify potential barriers to optimal implementation. New evidence may prompt a review of the guidelines.

Disclosure of Interest

None Declared

Information

Type
Abstract
Creative Commons
Creative Common License - CCCreative Common License - BY
This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.
Copyright
© The Author(s), 2025. Published by Cambridge University Press on behalf of European Psychiatric Association
Submit a response

Comments

No Comments have been published for this article.